XM does not provide services to residents of the United States of America.
T
T

ThermoFisher

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Thermo Fisher's plant making infant RSV drug breached FDA rules, documents show

EXCLUSIVE-Thermo Fisher's plant making infant RSV drug breached FDA rules, documents show Thermo Fisher's Greenville, N.C. plant has been found in breach of US FDA regulations, including twice this year FDA's most recent inspection of Thermo Fisher plant found shortfalls in manufacturing of Sanofi's and AstraZeneca's Beyfortus RSV treatment Sanofi says the FDA findings were addressed and all Beyfortus doses were approved by FDA before they were shipped Adds graphic By Patrick Wingrove Oct 4 (Reu
A
S
T

Thermo Fisher falls after Reuters report on breaches at North Carolina plant

BUZZ-Thermo Fisher falls after Reuters report on breaches at North Carolina plant ** Shares of contract drug manufacturer Thermo Fisher TMO.N down 1.6% at $591.31 premarket ** One of TMO's manufacturing plants has repeatedly breached rules meant to ensure drugs are free of contamination in the last decade, Reuters repored , citing FDA documents ** The plant, located in Greenville, North Carolina is among the largest contract drug manufacturing plants in the U.S.
U
T

Thermo Fisher's plant making infant RSV drug breached FDA rules, documents show

CORRECTED-EXCLUSIVE-Thermo Fisher's plant making infant RSV drug breached FDA rules, documents show Corrects paragraph 26 to Novo Holdings from Novo Nordisk Thermo Fisher's Greenville, N.C. plant has been found in breach of US FDA regulations, including twice this year FDA's most recent inspection of Thermo Fisher plant found shortfalls in manufacturing of Sanofi's and AstraZeneca's Beyfortus RSV treatment Sanofi says the FDA findings were addressed and all Beyfortus doses were approved by FDA b
A
S
T

Thermo Fisher Scientific Expands Oral Solid Dose Development And Manufacturing Capabilities Across North America

BRIEF-Thermo Fisher Scientific Expands Oral Solid Dose Development And Manufacturing Capabilities Across North America Sept 26 (Reuters) - Thermo Fisher Scientific Inc TMO.N : THERMO FISHER SCIENTIFIC EXPANDS ORAL SOLID DOSE DEVELOPMENT AND MANUFACTURING CAPABILITIES ACROSS NORTH AMERICA Source text for Eikon: ID:nBwc3wlpHa Further company coverage
T

ASML supplier NTS Group opens Singapore plant

ASML supplier NTS Group opens Singapore plant AMSTERDAM, Sept 20 (Reuters) - NTS Group, a Dutch-based maker of "mechatronic" equipment used by semiconductor firms including neighbouring giant ASML ASML.AS , on Friday opened a major new assembly and manufacturing plant in Singapore. Mechatronics integrate mechanical, electronics and software systems. NTS is known as a supplier of highly complex systems used in metrology, where top names include Lam Research, Applied Materials AMAT.O , Thermo Fish
A
L
T

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.